Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
Open Access
- 14 July 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (10), 936-948
- https://doi.org/10.1111/dom.12503
Abstract
To investigate the efficacy and tolerability of empagliflozin added to basal insulin‐treated type 2 diabetes. Patients inadequately controlled [glycated haemoglobin (HbA1c) >7 to ≤10% (>53 to ≤86 mmol/mol)] on basal insulin (glargine, detemir, NPH) were randomized to empagliflozin 10 mg (n = 169), empagliflozin 25 mg (n = 155) or placebo (n = 170) for 78 weeks. The baseline characteristics were balanced among the groups [mean HbA1c 8.2% (67 mmol/mol), BMI 32.2 kg/m2]. The basal insulin dose was to remain constant for 18 weeks, then could be adjusted at investigator's discretion. The primary endpoint was change from baseline in HbA1c at week 18. Key secondary endpoints were changes from baseline in HbA1c and insulin dose at week 78. At week 18, the adjusted mean ± standard error changes from baseline in HbA1c were 0.0 ± 0.1% (−0.1 ± 0.8 mmol/mol) for placebo, compared with −0.6 ± 0.1% (−6.2 ± 0.8 mmol/mol) and −0.7 ± 0.1% (−7.8 ± 0.8 mmol/mol) for empagliflozin 10 and 25 mg, respectively (both p < 0.001). At week 78, empagliflozin 10 and 25 mg significantly reduced HbA1c, insulin dose and weight vs placebo (all p < 0.01), and empagliflozin 10 mg significantly reduced systolic blood pressure vs placebo (p = 0.004). Similar percentages of patients had confirmed hypoglycaemia in all groups (35–36%). Events consistent with urinary tract infection were reported in 9, 15 and 12% of patients on placebo, empagliflozin 10 and 25 mg, and events consistent with genital infection were reported in 2, 8 and 5%, respectively. Empagliflozin for 78 weeks added to basal insulin improved glycaemic control and reduced weight with a similar risk of hypoglycaemia to placebo.Keywords
Funding Information
- Boehringer Ingelheim
- Eli Lilly and Company
- Pfizer
- Roche
- Bristol-Myers Squibb
- AstraZeneca
- Johnson and Johnson
This publication has 37 references indexed in Scilit:
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetic Medicine, 2012
- Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetesCurrent Medical Research and Opinion, 2011
- Three-Year Efficacy of Complex Insulin Regimens in Type 2 DiabetesNew England Journal of Medicine, 2009
- Intensification lessons with modern premixes: From clinical trial to clinical practiceDiabetes Research and Clinical Practice, 2008
- Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?Diabetes Care, 2008
- Psychological Insulin Resistance in Patients With Type 2 DiabetesDiabetes Care, 2005
- Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 DiabetesDiabetes Care, 2005
- The Burden of Treatment Failure in Type 2 DiabetesDiabetes Care, 2004
- The Treat-to-Target TrialDiabetes Care, 2003